Safety, clinical activity and biomarker results from a Phase Ib study of erlotinib plus atezolizumab in advanced NSCLC
Refereed conference paper presented and published in conference proceedings


Full Text

Other information
All Author(s) ListRUDIN M Charles, CERVANTES Andres, DOWLATI Afshin, BESSE Benjamin, MA Buig Yue Brigette, COSTA Danniel, SCHMID Peter, HEIST Rebecca, VILLAFLOR Victoria, SARKAR Indrani, HUSENI Mahrukh, FOSTER Paul
Name of Conference17th World Conference on Lung Cancer 2016, 4–7 December 2016, Vienna, Austria
Start Date of Conference04/12/2016
Country/Region of ConferenceAustria
Proceedings Title17th World Conference on Lung Cancer 2016, 4–7 December 2016, Vienna, Austria
Year2016
Month12
Day4
Place of PublicationAustria, Vienna
Pagesone
LanguagesEnglish-United Kingdom
Keywordsbiomarker; atezolizumab

Last updated on 2018-22-01 at 20:46